

## Erratum to: Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology

Sanjay Kalra

To view enhanced content go to [www.diabetestherapy-open.com](http://www.diabetestherapy-open.com)

Received: January 6, 2015 / Published online: January 15, 2015

© The Author(s) 2015. This article is published with open access at [Springerlink.com](http://Springerlink.com)

Erratum to: Diabetes Ther (2014) 5(2):355–366  
DOI 10.1007/s13300-014-0089-4

In Table 3 on page 358 under the heading Dose modifications for Empagliflozin the sentence “Contraindicated in patients with creatinine clearance <45 ml/min” should read “Stopped in patients with creatinine clearance <45 ml/min”.

**Open Access.** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

---

The online version of the original article can be found under doi:[10.1007/s13300-014-0089-4](https://doi.org/10.1007/s13300-014-0089-4).

---

S. Kalra (✉)  
Bharti Hospital and B.R.I.D.E., Karnal, India  
e-mail: [brideknl@gmail.com](mailto:brideknl@gmail.com)